CONSHOHOCKEN, Pa., Aug. 21 /PRNewswire-FirstCall/ -- CardioNet, Inc. , a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that it has named Ronald Ahrens and Kirk Gorman to its Board of Directors. The appointments of Mr. Ahrens and Mr. Gorman increase CardioNet’s Board to a total of nine members.
Arie Cohen, CardioNet President and CEO, commented, “Ron and Kirk are tremendous additions to our Board, and we are very pleased and fortunate to have the opportunity to gain from their years of experience across a broad spectrum of healthcare and business disciplines. Their appointments, along with the recent naming of Randy Thurman as Executive Chairman, serve to further strengthen and diversify our Board as we continue to execute our growth strategy and establish CardioNet’s mobile cardiac outpatient telemetry system as the best-in-class in the arrhythmia monitoring market.”
A healthcare industry veteran with over forty years of senior executive and management experience, Mr. Ahrens most recently served as President of Merck Consumer Healthcare Group Worldwide. Prior to his tenure at Merck, Mr. Ahrens held several positions within Bristol Myers Squibb, including Consumer Group President North America and President, Bristol Myers Products Division. In addition, Mr. Ahrens has held executive and management positions at Richardson Vicks and Procter & Gamble.
Mr. Ahrens has also established a strong track record on several Boards of Directors. Currently, he serves as a Non-Executive Advisor to the Board of Johnson & Johnson Merck, and is a Board member of Temptime Corporation, a privately held company that supplies vaccine vial monitors, and ULURU, Inc., an AMEX-listed specialty pharmaceutical company specializing in wound care. Previously, Mr. Ahrens was on the Boards of VIASYS Healthcare, Closure Medical Corporation, St. Ives and Alcide.
Mr. Gorman is currently Senior Vice President and Chief Financial Officer of Jefferson Health Systems, the largest hospital system in Philadelphia. Prior to Jefferson Health Systems, he was Senior Vice President and Chief Financial Officer of Universal Health Services, the country’s fifth largest investor owned hospital chain, and President, Chief Financial Officer and member of the Board of Trustees of Universal Health Realty Income Trust, a NYSE-listed healthcare REIT. Mr. Gorman began his career with Mellon Bank, where he served in numerous credit, cash management, and corporate banking functions.
Mr. Gorman also brings extensive Board experience to CardioNet. Currently, he serves as Chairman of the Board of Care Investment Trust, a NYSE-listed healthcare REIT, and is a member of the board of IASIS Healthcare LLC, an owner and operator of community-focused hospitals. Mr. Gorman also served on the Boards of VIASYS Healthcare, Physician Dialysis, Inc. and HCF Guernsey, Ltd.
About CardioNet
CardioNet, Inc. is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as the CardioNet System. More information can be found at http://www.cardionet.com .
Forward Looking Statements
This press release includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects and the prospects for our products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the success of our sales and marketing initiatives, our ability to attract and retain talented sales personnel, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection and litigation. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: CardioNet, Inc.
CONTACT: Marty Galvan, Investor Relation, of CardioNet, Inc.,
+1-800-908-7103, investorrelations@cardionet.com
Web site: http://www.cardionet.com/
